The 12-month diagnosed prevalent cases of schizophrenia are expected to increase from 3.40 million in 2021 to 3.49 million in 2031 across the seven major markets (7MM*), at an annual growth rate (AGR) of 0.26%, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Schizophrenia Epidemiology Analysis and Forecast, 2021-2031’, reveals that the US will have the highest number of 12-month diagnosed prevalent cases of schizophrenia among the 7MM, increasing at an annual growth rate (AGR) of 0.75% between 2021­ and 2031. The major drivers can be attributed to better diagnosis and population dynamics.

Rahul N Ravi, Epidemiologist at GlobalData, comments: “Schizophrenia is a chronic and debilitating mental illness, characterized by delusions, hallucinations, disorganized speech, trouble with thinking, and a lack of motivation. It is among the most disabling and economically catastrophic medical disorders globally.

“The diagnosis and treatment of persons with schizophrenia should contain recommendations on both the diagnostic work-up and the pharmacological, psychotherapeutic, and psychosocial treatment over their entire life span. The treatment of persons with schizophrenia must be multi-professional with a basic attitude of empathy, respect, and appreciation on the part of the caregivers.”

*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan